Fraction of Osteocalcin Endothelial Progenitor Cells and Cardiovascular Risk

Circ Res. 2023 Apr 28;132(9):1162-1164. doi: 10.1161/CIRCRESAHA.122.322407. Epub 2023 Mar 29.

Authors

Ilke Ozcan¹, Yoshihisa Kanaji^{1

2}, Arush Rajotia¹, Takumi Toya^{1

3}, Nadia Akhiyat¹, David Morse¹, Lilach O Lerman⁴, Amir Lerman¹

Affiliations

¹ Department of Cardiovascular Medicine (I.O., Y.K., A.R., T.T., N.A., D.M., A.L.)), Mayo Clinic, Rochester, MN.
² Division of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Ibaraki, Japan (Y.K.).
³ Division of Cardiology, National Defense Medical College, Tokorozawa, Saitama, Japan (T.T.).
⁴ Division of Nephrology and Hypertension (L.O.L.), Mayo Clinic, Rochester, MN.

PMID: 36987925
DOI: 10.1161/CIRCRESAHA.122.322407

No abstract available

Keywords: coronary artery disease; endothelial progenitor cells; heart failure; hyperlipidemias; osteocalcin.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Cardiovascular Diseases*
Coronary Artery Disease*
Endothelial Progenitor Cells*
Heart Disease Risk Factors
Humans
Osteocalcin
Risk Factors

Substances

Osteocalcin